Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
25 Apr 2018
Change (% chg)

$0.03 (+1.16%)
Prev Close
$2.58
Open
$2.58
Day's High
$2.62
Day's Low
$2.54
Volume
196,796
Avg. Vol
308,092
52-wk High
$4.24
52-wk Low
$0.57

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $303.11
Shares Outstanding(Mil.): 118.87
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.61 -- --
ROI: -371.47 -0.73 12.97
ROE: -- -2.77 14.84

SEC seeks to block ex-Aveo CFO's testimony about consulting counsel

The Securities and Exchange Commission is seeking to block the former chief financial officer of Aveo Pharmaceuticals Inc from testifying at his upcoming trial that he relied on lawyers before making statements the regulator claims were misleading.

Apr 18 2018

BRIEF-Aveo Quarterly Loss Per Share $0.08

* AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 13 2018

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

Feb 16 2018

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

Feb 12 2018

Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case

A federal magistrate judge on Friday ordered the former chief medical officer of Aveo Pharmaceuticals Inc to pay a $50,000 penalty, a third of what the U.S. Securities and Exchange Commission requested, to resolve civil fraud charges.

Feb 09 2018

SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec

The U.S. Securities and Exchange Commission is pushing to have the former chief medical officer of Aveo Pharmaceuticals Inc pay a $150,000 penalty and be barred for five years from serving as an officer or director of a public company for committing fraud.

Jan 02 2018

Aveo settles investor lawsuit over cancer drug for $15 mln, warrants

Aveo Pharmaceuticals Inc will settle claims it misled shareholders about the Food and Drug Administration's concerns regarding a kidney cancer drug it was developing by paying $15 million out of insurance and issuing warrants for affected investors to buy 2 million shares.

Dec 27 2017

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

Dec 26 2017

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

Dec 07 2017

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

Nov 30 2017

Competitors

Earnings vs. Estimates